Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience
Table 5
Risk for COVID-19-related mortality.
Covariate
Univariate analyses
Multivariate analyses
HR
95% CI
HR
95% CI
Age at SARS-CoV-2 infection diagnosis (per year)
1.06
1.05–1.08
<0.001
1.04
1.02–1.05
<0.001
Male recipient
1.82
1.22–2.69
0.003
1.39
0.93–2.08
0.11
Non-white recipient
1.82
1.23–2.69
0.002
1.45
0.94–2.21
0.09
Diabetes as a cause of ESKD vs other
2.41
1.67–3.50
<0.001
1.36
0.91–2.01
0.13
Living donor recipient
0.58
0.39–0.85
0.005
0.77
0.51–1.16
0.21
Previous transplant
0.54
0.32–0.93
0.03
0.94
0.53–1.66
0.83
Tacrolimus + MPA + prednisone maintenance vs other
1.05
0.73–1.53
0.78
Prednisone-based immunosuppression
2.37
1.11–5.09
0.03
1.28
0.57–2.86
0.55
Treatment of rejection before SARS-CoV-2 infection
0.89
0.13–6.24
0.89
Vaccinated
0.44
0.29–0.5
<0.001
0.47
0.31–0.71
<0.001
Baseline eGFR (per mL/min/1.73 m2)
0.98
0.97–0.99
<0.001
0.99
0.98–1.01
0.18
Interval from transplant to SARS-CoV-2 infection (per month)
1.02
1.0–1.04
0.007
1.01
1.0–1.05
0.003
Hospitalization
76.2
24.2–239.7
<0.001
24.3
6.9–85.7
<0.001
Respiratory symptoms for hospital admission
20.0
11.80–33.88
<0.001
2.73
1.52–4.89
<0.001
Bold values signify statistically significant with p value less than 0.05.
